Results 11 to 20 of about 3,632,283 (294)
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer [PDF]
Bladder CancerThe National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on ‘Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)’ led by the Bladder Cancer Task Force ...
Andrea Apolo +31 more
doaj +2 more sources
Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting [PDF]
Bladder Cancer, 2016 The advent of Omics technologies has been key to the molecular subclassification of urothelial bladder cancer. Several groups have used different strategies to this aim, with partially overlapping findings.
Seth P. Lerner +7 more
doaj +2 more sources
Urology, 1996 SummaryBladder cancer is the fourth most common cancer in England and Wales. The most common presenting symptom is macroscopic haematuria. The management options for superficial and invasive bladder cancer depend on the stage at presentation. Most superficial bladder cancers are managed by transurethral resection and cytoscopic follow-up. The prognosis
H Y, Leung, T R, Griffiths, D E, Neal
openaire +4 more sources
Current Treatment Options in Oncology, 2009 Bladder cancer is a complex disease of older patients with coexisting medical problems requiring multimodal therapy. For patients with localized bladder cancer, standard management for superficial disease includes transurethral resection with or without intravesical therapy, while muscle-invasive cancer is managed with neoadjuvant cisplatin- based ...
David J, Gallagher, Matthew I, Milowsky
+9 more sources
Microarray analysis of pathways involved in bladder cancer invasion and metastasis. [PDF]
, 2008 MDHypoxia-inducible genes have been linked to the aggressive phenotype of cancer. However, nearly all work on hypoxia-regulated genes has been conducted in vitro on cell lines.
Ord, Jonathan J
core +4 more sources
The Scientific World JOURNAL, 2011 To review the epidemiology, diagnosis, and management of all stages of bladder cancer with an emphasis on studies published within the last year.Smoking continues to be the most important risk factor for the development of bladder cancer, and this risk has increased over time.
Todd M, Morgan +2 more
openaire +5 more sources
An Intravesical Akkermansia muciniphila-Based Chemo-Immunotherapeutic Platform for Bladder Cancer. [PDF]
Adv Sci (Weinh)Pasteurized Akkermansia muciniphila is engineered into an intravesical F127/doxorubicin platform that couples localized chemotherapy with immune remodeling. By inducing apoptosis, ferroptosis, and immunogenic cell death, this chemo‐immunotherapeutic system enhances dendritic‐cell maturation, antigen cross‐presentation, and tumor‐specific CD8+ T‐cell ...
Li R +11 more
europepmc +2 more sources
Nature Reviews Disease Primers, 2017 Bladder cancer is a highly prevalent disease and is associated with substantial morbidity, mortality and cost. Environmental or occupational exposures to carcinogens, especially tobacco, are the main risk factors for bladder cancer. Most bladder cancers are diagnosed after patients present with macroscopic haematuria, and cases are confirmed after ...
Oner, Sanli +6 more
openaire +2 more sources
Human urinary exosomes in bladder cancer patients : properties, concentrations and possible clinical application [PDF]
, 2015 OBJECTIVE: High grade bladder cancer is extremely aggressive. Early detection is thus an important challenge. De- velopment of non-invasive diagnostic tools particularly using urine samples could be of importance in the diagnosis and surveillance of ...
Mullen, Peter +15 more
core +1 more source
Quality of Life and Health State Utilities in Bladder Cancer
, 2022 Background: Bladder cancer treatments may variably impact health-related quality of life (QOL). Objective: To characterize the quality of life of patients with bladder cancer at various time points across the continuum of bladder cancer care from non ...
Amy Guo +17 more
core +1 more source